BioGaia AB (publ) (BIOG-B.ST)
Stockholm · SEK · Healthcare · Drug Manufacturers - Specialty & Generic
SEK 123.80 (-0.56%) as of
Key statistics
- Market cap
- 12.52B
- P/E (TTM)
- 31.26
- Forward P/E
- 28.59
- EPS (TTM)
- 3.96
- Dividend yield
- 1.32%
- 52-week range
- 96.20 – 136.30
- Beta
- 0.27
- Revenue (TTM)
- 1.65B
- Profit margin
- 23.67%
- Analyst target
- SEK 158.00
- Volume
- 161.52k
About BioGaia AB (publ)
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablets, and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment offers packaging solutions. It sells its products through distribution partners or through its own distribution channels. The company was incorporated in 1990 and is headquartered in Stockholm, Sweden.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Stockholm, Sweden
- Employees
- 251
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.